| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1007276554 |
| P356 | DOI | 10.1186/AR2462 |
| P932 | PMC publication ID | 2582808 |
| P698 | PubMed publication ID | 19007426 |
| P5875 | ResearchGate publication ID | 23471812 |
| P2093 | author name string | Francis Berenbaum | |
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) | Q24674132 | ||
| Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs | Q28166597 | ||
| Non-narcotic analgesic dose and risk of incident hypertension in US women | Q28187789 | ||
| Acetaminophen, aspirin, and chronic renal failure | Q28191910 | ||
| Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction | Q28196509 | ||
| Lifetime nonnarcotic analgesic use and decline in renal function in women | Q28209660 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial | Q28211435 | ||
| Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study | Q28218304 | ||
| Building a better aspirin: gaseous solutions to a century-old problem | Q28218664 | ||
| Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
| Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk | Q28219220 | ||
| Frequency of analgesic use and risk of hypertension among men | Q28219460 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q31119321 | ||
| EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q33260652 | ||
| OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence | Q33295110 | ||
| OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines | Q33320085 | ||
| Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s | Q33974678 | ||
| The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis | Q34006192 | ||
| Nonsteroidal anti-inflammatory drugs | Q34057579 | ||
| Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs | Q34093824 | ||
| A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee | Q34315035 | ||
| Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials | Q34565640 | ||
| Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association | Q34576407 | ||
| Renal effects of nonselective NSAIDs and coxibs. | Q34709255 | ||
| Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis | Q34726199 | ||
| Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population | Q34994889 | ||
| Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium | Q35052876 | ||
| Paracetamol in osteoarthritis of the knee | Q35554393 | ||
| A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis | Q35555299 | ||
| Burden of major musculoskeletal conditions. | Q35622610 | ||
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | Q36591918 | ||
| Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? | Q37044230 | ||
| Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs | Q37172161 | ||
| Financial cost of osteoarthritis in France. The "COART" France study | Q40381153 | ||
| Renal complications of nonsteroidal anti-inflammatory drugs | Q40775893 | ||
| Renal complications associated with use of nonsteroidal anti-inflammatory agents. | Q40972754 | ||
| NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis | Q41857575 | ||
| Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats | Q43517069 | ||
| Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs | Q43707204 | ||
| Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada | Q43780214 | ||
| The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus | Q45236720 | ||
| The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. | Q50767186 | ||
| Direct medical costs unique to people with arthritis. | Q50962364 | ||
| Pain-related fear and daily functioning in patients with osteoarthritis. | Q50995762 | ||
| Coxibs and NSAIDs--is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. | Q53232396 | ||
| Direct and indirect costs attributable to osteoarthritis in active subjects. | Q53241700 | ||
| Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U.S. National Health and Nutrition Examination Survey, 1991-1994 | Q64129232 | ||
| A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure | Q70565061 | ||
| NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects | Q73094778 | ||
| Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs | Q73592253 | ||
| Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study | Q81243519 | ||
| Impact of osteoarthritis: results of a nationwide survey of 10,000 patients consulting for OA | Q81684221 | ||
| P433 | issue | Suppl 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| non-steroidal anti-inflammatory drug | Q188724 | ||
| anti-inflammatory agent | Q581996 | ||
| medical research | Q2752427 | ||
| P304 | page(s) | S1 | |
| P577 | publication date | 2008-10-17 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | New horizons and perspectives in the treatment of osteoarthritis | |
| P478 | volume | 10 Suppl 2 |
| Q56659563 | Case-control study of knee osteoarthritis and lifestyle factors considering their interaction with physical workload |
| Q40396278 | Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats. |
| Q35644901 | Chitosan enriched three-dimensional matrix reduces inflammatory and catabolic mediators production by human chondrocytes |
| Q42393176 | Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits |
| Q39954568 | Effects of l-Carnitine Supplementation on Serum Inflammatory Factors and Matrix Metalloproteinase Enzymes in Females with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q38196985 | Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project |
| Q48035366 | Frequency of joint hypermobility in Turkish patients with knee osteoarthritis: a cross sectional multicenter study |
| Q46563144 | Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes |
| Q39152231 | Inadequate pain relief among patients with primary knee osteoarthritis. |
| Q57480564 | Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD) |
| Q36047700 | Osteoarthritis: New Perspectives |
| Q90445554 | PI3K/Akt and caspase pathways mediate oxidative stress-induced chondrocyte apoptosis |
| Q33631650 | Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes |
| Q33629459 | Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee |
| Q34479182 | Risk factors for radiographic tibiofemoral knee osteoarthritis: the wuchuan osteoarthritis study |
| Q42288148 | S100A8/A9 increases the mobilization of pro-inflammatory Ly6Chigh monocytes to the synovium during experimental osteoarthritis. |
| Q39182757 | Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen |
| Q48300377 | Safety and toxicological evaluation of undenatured type II collagen |
| Q26850147 | Targets, models and challenges in osteoarthritis research |
| Q37816952 | The bone-cartilage unit in osteoarthritis |
| Q84723771 | Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol |
Search more.